Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity|
- Increase of insulin sensitivity in apparently healthy men and woman evaluate by means of i.v. glucose tolerance test (PTEVGMR).
- Reduction antropometric measures associated with insulin resistance and arterial hypertension.
|Study Start Date:||July 2002|
|Estimated Study Completion Date:||December 2004|
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.
Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days
Washout period: 30 days
Please refer to this study by its ClinicalTrials.gov identifier: NCT00162799
|Unitat de Diabetologia, Endocrinologia y Nutrición Hosp Josep Trueta|
|Girona, Spain, 17007|
|Principal Investigator:||Jose Manuel Fernández del Real, Dr||Unidad Diabetología. Serv Endocrino Hosp Josep Trueta|